|

BMS-986368 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: CC-97489

Pipeline

Phase 2: 2

Top Sponsors

  • Celgene2

Indications

  • Multiple Sclerosis Spasticity1
  • Agitation1
  • Alzheimer's Disease1
  • Multiple Sclerosis1
  • Alzheimer Disease1

Birmingham, Alabama1 trial

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Local Institution - 0033

Phase 2

Homewood, Alabama1 trial

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Local Institution - 0046

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.